| IL-15 super-agonist (ALT-803) enhances natural killer (NK) cell function against ovarian cancer M Felices, S Chu, B Kodal, L Bendzick, C Ryan, AJ Lenvik, KLM Boylan, ... Gynecologic oncology 145 (3), 453-461, 2017 | 131 | 2017 |
| Harnessing features of adaptive NK cells to generate iPSC-derived NK cells for enhanced immunotherapy KV Woan, H Kim, R Bjordahl, ZB Davis, S Gaidarova, J Goulding, ... Cell Stem Cell 28 (12), 2062-2075. e5, 2021 | 125 | 2021 |
| Cytokine-induced memory-like natural killer cells have enhanced function, proliferation, and in vivo expansion against ovarian cancer cells LD Uppendahl, M Felices, L Bendzick, C Ryan, B Kodal, P Hinderlie, ... Gynecologic oncology 153 (1), 149-157, 2019 | 112 | 2019 |
| NK-cell-mediated targeting of various solid tumors using a B7-H3 tri-specific killer engager in vitro and in vivo DA Vallera, S Ferrone, B Kodal, P Hinderlie, L Bendzick, B Ettestad, ... Cancers 12 (9), 2659, 2020 | 88 | 2020 |
| Novel CD19-targeted TriKE restores NK cell function and proliferative capacity in CLL M Felices, B Kodal, P Hinderlie, MF Kaminski, S Cooley, DJ Weisdorf, ... Blood advances 3 (6), 897-907, 2019 | 87 | 2019 |
| Potent cytolytic activity and specific IL15 delivery in a second-generation trispecific killer engager M Felices, TR Lenvik, B Kodal, AJ Lenvik, P Hinderlie, LE Bendzick, ... Cancer immunology research 8 (9), 1139-1149, 2020 | 60 | 2020 |
| Dual antigen–targeted off-the-shelf NK cells show durable response and prevent antigen escape in lymphoma and leukemia F Cichocki, JP Goodridge, R Bjordahl, S Mahmood, ZB Davis, ... Blood, The Journal of the American Society of Hematology 140 (23), 2451-2462, 2022 | 47 | 2022 |
| A HER2 tri-specific NK cell engager mediates efficient targeting of human ovarian cancer DA Vallera, F Oh, B Kodal, P Hinderlie, MA Geller, JS Miller, M Felices Cancers 13 (16), 3994, 2021 | 33 | 2021 |
| Early assessment of dosimetric and biological differences of total marrow irradiation versus total body irradiation in rodents S Hui, Y Takahashi, SG Holtan, R Azimi, D Seelig, M Yagi, J Ingvalson, ... Radiotherapy and Oncology 124 (3), 468-474, 2017 | 26 | 2017 |
| A tri-specific killer engager against mesothelin targets NK cells towards lung cancer PR Kennedy, DA Vallera, B Ettestad, C Hallstrom, B Kodal, DA Todhunter, ... Frontiers in immunology 14, 1060905, 2023 | 16 | 2023 |
| TEM8 Tri-specific Killer Engager binds both tumor and tumor stroma to specifically engage natural killer cell anti-tumor activity MF Kaminski, L Bendzick, R Hopps, M Kauffman, B Kodal, Y Soignier, ... Journal for Immunotherapy of Cancer 10 (9), 2022 | 15 | 2022 |
| Allogeneic NK cells eradicate myeloblasts but not neoplastic mast cells in systemic mastocytosis associated with acute myeloid leukemia C Ustun, S Williams, S Skendzel, B Kodal, M Arock, J Gotlib, DA Vallera, ... American journal of hematology 92 (5), E66-E68, 2017 | 9 | 2017 |
| Reverse translation identifies the synergistic role of immune checkpoint blockade and IL15 to enhance immunotherapy of ovarian cancer M Felices, E Wesley, LE Bendzick, B Kodal, R Hopps, B Grzywacz, ... Cancer immunology research 11 (5), 674-686, 2023 | 8 | 2023 |
| Off-the-shelf, multiplexed-engineered iPSC-derived NK cells mediate potent multi-antigen targeting of B-cell malignancies with reduced cytotoxicity against healthy B cells F Cichocki, JP Goodridge, R Bjordahl, S Gaidarova, S Mahmood, ... Blood 138, 407, 2021 | 6 | 2021 |
| P618: second-generation CD19 targeting tri-specific killer engager drives robust nk cell function against B cell malignancies J Miller, B Kodal, P Hinderlie, D Vallera, G Berk, V Bachanova, M Felices HemaSphere 6, 517-518, 2022 | 3 | 2022 |
| 126P Novel B7-H3 targeting dual nanobody NK cell engagers display robust activity against a broad spectrum of solid and hematologic malignancies N Zorko, M Felices, A Merino, J Walker, B Kodal, A Lenvik, ZB Davis, ... Annals of Oncology 32, S1433, 2021 | 3 | 2021 |
| 1202 Tri-specific killer engagers target natural killer cells towards mesothelioma PP Kennedy, Q Kile, B Jacobson, B Ettestad, N Zorko, C Hallstrom, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | 2 | 2022 |
| 470 targeting pan-tumor associated antigen B7H3 via combination of tri-specific killer engager and off-the-shelf NK cell therapy enhances specificity and function against a … J Miller, N Zorko, B Kodal, Z Davis, A Lenvik, T Lenvik, J Walker, D Vallera, ... Journal for ImmunoTherapy of Cancer 8 (Suppl 3), 2020 | 2 | 2020 |
| Second-generation camelid trike induces improved NK cell mediated targeting of AML in pre-clinical models M Felices, CE Eckfeldt, TR Lenvik, B Kodal, AJ Lenvik, L Bendzick, ... Blood 130, 4465, 2017 | 2 | 2017 |
| Immunotherapeutic development of a tri-specific NK cell engager recognizing BCMA F Oh, M Felices, B Kodal, JS Miller, DA Vallera Immuno 3 (2), 237-249, 2023 | 1 | 2023 |
